Daily Stock Opinions and Ratings

Opinions

Chris Damas Aurora Cannabis ACB-T COMMENT Aug 31, 2017

It is one of his top 4 companies. They have diluted their shares substantially. They have over $100 million in debt. They have the most upside and also the most downside.

Chris Damas

Unknown

Unlock Rating

$2.490

Stock price when the opinion was issued

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

The cannabis sector has been thrashed and still not good value--no earnings, uncertain sales. Very risky and good luck to you. He doesn't see the fundamentals improving.

DON'T BUY

He feels all cannabis stocks are gambling stocks. A maturing debenture is expected to keep downward pressure on the share price. There is no assurance that any existing company will be a survivor -- it is simply too early. No one is making money in this space. Without being able to predict revenues and expenses, it is too risky. He would stay away from these.

BUY

They each have their own strengths. He would pick Canopy (WEED-T) because they are the 800 lb gorilla. Aurora has lots of news about balance sheet challenges but they have low costs that he thinks will still come down further.

DON'T BUY

He saw the bubble coming in cannabis. Take a look at the financial balance sheets and see how much money they owe. He owns one company in the space that also owns liquor stores. You will see more companies go under in this space. He only buys companies that have been around for 10 years.

SELL

Don't buy cannabis stocks here. Their earnings just aren't there. You can buy good value companies at discounts to book value so why go for this one. Move on. It is an opportunity to upgrade your portfolio.

HOLD

It's been a wild ride. The valuation across all the names are still quite high. With what we are seeing with legislation in the US, he would still tend to look at these. Stick with it.

DON'T BUY

Lots of opportunity in the US. Guilty of using easy money to build massive facilities. Big writedowns. Big equity offering. Doesn't see an imminent big export market. Longer term potential, but it's an outside probability.

DON'T BUY

Look at what the opportunity is. The US has increased medical and recreational use, plus favourable legislation. Doesn't have the strongest set of assets in the US, so he'd favour MSOs over ACB. Europe is the longer-range opportunity, where it has a foothold.

COMMENT

The problem is that parts of the world weed grows easily, so the economics don't work. The big opportunity will happen when the US legalizes weed federal, then weed shares will pop. If you're under water this, take the tax loss.

DON'T BUY

Avoid the sector. High risk, speculative. Doesn't see catalysts to drive the sector higher, especially if Republicans succeed in the US election.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Chris Damas Aurora Cannabis ACB-T COMMENT Aug 31, 2017

You might be interested:

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Aurora Cannabis(ACB-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Eric Nuttall

The Panic-Proof Portfolio (Stockchase Research)

David Burrows

Larry Berman CFA, CMT, CTA

Stockchase Insights